Vimarsana
Biggest News Aggregation in the World

Marketing Application News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Marketing Application. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Marketing Application Today - Breaking & Trending Today

Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma - Vimarsana News

Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma

/PRNewswire/ -- Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA...

Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease -December 19, 2023 at 07:31 am EST - Vimarsana News

Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease -December 19, 2023 at 07:31 am EST

NEW YORK, Dec. 19, 2023 -- Anavex Life Sciences Corp. , a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and...

Anavex Life Sciences Corp. Receives Agreement from the Committee for Medicinal Products for Human Use for the Submission of A Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease - Vimarsana News

Anavex Life Sciences Corp. Receives Agreement from the Committee for Medicinal Products for Human Use for the Submission of A Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease

Anavex Life Sciences Corp. announced that the Committee for Medicinal Products for Human Use within the European Medicines Agency agreed that oral blarcamesine for Alzheimer's disease is eligible...

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma - Vimarsana News

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., October 13, 2023--BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval of BRUKINSA® (zanubrutinib), a Bruton’s tyrosine kinase inhibitor (BTKi), in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicul

Source: yahoo.com
Nevro Announces Enrollment of First Patient in PDN Sensory Study - Vimarsana News

Nevro Announces Enrollment of First Patient in PDN Sensory Study

/PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of...